Financials

  • Market Capitalization 295.4162 M
  • Employee 80
  • Founded 1989
  • CEO N/A
  • Website www.amarincorp.com
  • Headquarter United Kingdom
  • FIGI BBG000BPYG99
  • Industry Fabricants de Médicaments — Généralités
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
-155.06
ratio cours/chiffre d'affaires
27.11

Amarin Corporation plc - American Depositary Shares, each repre

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa, a prescription grade omega-3 fatty acid. In July 2012, their lead-candidate drug named Vascepa received FDA-approval, competing against GlaxoSmithKline's Lovaza.

Nouvelles